ValuEngine upgraded shares of Northwest Biotherapeutics (OTCMKTS:NWBO) from a hold rating to a buy rating in a report published on Thursday.
Shares of OTCMKTS:NWBO opened at $0.21 on Thursday. Northwest Biotherapeutics has a 1 year low of $0.16 and a 1 year high of $0.40.
Northwest Biotherapeutics (OTCMKTS:NWBO) last issued its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.28 million during the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Featured Story: How much money do you need to begin day trading?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.